PhinC increases the efficiency of drug development with statistical analysis and pharmacometrics. We use Model-Based Drug Development (MBDD) on early phase to optimize trial design and reduce development time.

In collaboration with Vitalea, Inc., Rosa will present a poster at the 2011 American Society for Clinical Pharmacology and Therapeutics in Dallas, TX entitled "Compartmental Analysis of Urosodiol PK in Neonates using AMS" at 8:00 am on March 4, 2011.